Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug;8(8):606-10.
doi: 10.1007/s12094-006-0067-z.

Dermatofibrosarcoma protuberans: review of 20-years experience

Affiliations

Dermatofibrosarcoma protuberans: review of 20-years experience

Jaime Ruiz-Tovar et al. Clin Transl Oncol. 2006 Aug.

Abstract

Introduction: Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue neoplasm with low-intermediate grade of malignancy. It is a locally aggressive tumour with a high recurrence rate. Surgical excision with adequate margins is the main treatment.

Materials and methods: We describe the clinicopathological features of 21 cases of DFSP. The mean size of the lesions was 5.6 cm, mostly located in trunk. 61.9% of the cases underwent surgical excision without previous biopsy. 52.4% of the patients presented positive margins, that required surgical extension.

Results: The recurrence rate was 28.6% (6 cases), five of them local recurrences treated with new surgical excision with wide margins. Median period free of illness was 32.5 months. Medium follow-up period was 33.25 months.

Conclusions: DFSP has a locally high recurrence rate, that has been associated to inadequate surgical margins. The histological knowledge preoperatively would permit surgical excision with adequate margins, and probably this could reduce the recurrence rate. Radiotherapy could avoid the surgical extension of margins in these cases with positive ones. Chemotherapy could be indicated in metastasic cases. Most recurrences appear in the first 3 years, but it is important a long-term follow-up of these patients.

PubMed Disclaimer

References

    1. Cancer. 2000 Jun 15;88(12):2711-20 - PubMed
    1. Anticancer Drugs. 2005 Apr;16(4):461-6 - PubMed
    1. Cancer. 2004 Dec 1;101(11):2503-8 - PubMed
    1. Eur J Surg Oncol. 1999 Aug;25(4):392-7 - PubMed
    1. Eur J Surg Oncol. 1992 Jun;18(3):241-8 - PubMed

LinkOut - more resources